NCT02617095View on ClinicalTrials.gov

Comparison of the Efficacy and Safety of T2762 Versus Optive® in the Treatment of Moderate to Severe Dry Eye Syndrome

NATerminatedINTERVENTIONAL

Enrollment

64

Participants

Timeline

Start Date

February 28, 2015

Primary Completion Date

June 30, 2016

Study Completion Date

October 31, 2016

Conditions

Dry Eye Syndrome

Interventions

DEVICE

T2762

One drop in each eye 3 to 6 times daily

DEVICE

Optive

One drop in each eye 3 to 6 times daily

Trial Locations (1)

63000

Laboratoires Théa, Clermont-Ferrand

Sponsors

Lead Sponsor

Laboratoires Thea

All Listed Sponsors

lead

Laboratoires Thea

INDUSTRY